The Best of Annual Meeting 2019

Login to Purchase Now!

AMCP has compiled the best sessions from Annual Meeting 2019 for those of you who were not able to attend the meeting, or those of you who attended but missed some of the sessions.  Here are the home study actvities included in this set and ready to challenge and enhance your professional practice.

  • Brand and Generic Drugs in Development
  • Drug Pricing Reform Efforts: The Blueprint Turns 1 Year Old
  • Federal and State Legislative and Regulatory Update
  • It’s an ART: Formulary and Drug Use Management Strategies for HIV Medications
  • Measuring Value of an IDN Specialty Pharmacy Therapy Management Program for Biologics
  • Medicare Formulary Updates Impact
  • Specialty Pharmaceuticals in Development
  • Strategies for Staying Ahead of Specialty Drug Trends: Focus on the Medical Pharmacy Benefit
  • The Copay Card Conundrum: Examining the Usage, Regulation, and Management of Direct-to-Consumer Funding Programs
  • The Current State of Value-Based Contracting

Pick and choose individual sessions from the catalog or purchase The Best of AMCP Annual Meeting 2019: The Top Ten most highly rated sessions, according to attendance and post-meeting surveys.

Products

Found 10
Sort by
Home Study Programs
Log In

Measuring Value of an IDN Specialty Pharmacy Therapy Management Program for Biologics

Gene therapy is a promising treatment option for a number of diseases, including inherited disorders, some types of cancer, and certain viral infections. The first gene therapy approvals in the United States occurred in 2017.
IDN
Home Study Programs
Log In

Medicare Formulary Updates Impact

Contact Hours: 1.25. The Centers for Medicare and Medicaid (CMS) continues to critically evaluate formulary regulations and guidance to help lower drug costs.
Medicare
Home Study Programs
Log In

Drug Pricing Reform Efforts: The Blueprint Turns 1 Year Old

Contact Hours: 1.25. Since President Trump released his administration’s Drug Pricing Blueprint in May 2018, health care stakeholders have been anticipating changes to drug pricing policy.
Drug Pricing
Home Study Programs
Log In

Federal and State Legislative and Regulatory Update 2019

Contact Hours: 1.25. This must-attend session will bring you timely updates on the latest federal and state legislative and regulatory actions of interest to managed care and specialty pharmacy professionals.
Law
Home Study Programs
Log In

Strategies for Staying Ahead of Specialty Drug Trends: Focus on the Medical Pharmacy Benefit

Contact Hours 1.25. For the tenth consecutive year, specialty pharmaceutical growth has far exceeded that of traditional drugs.
Medical Pharmacy Benefit
Home Study Programs
Log In

It’s an ART: Formulary and Drug Use Management Strategies for HIV Medications

Contact Hours: 1.25. As people with HIV age, the focus of disease management places more emphasis on the safety of long-term medication use and managing comorbidities. The advantages of safer, more efficacious medications also come with increased cost.
HIV
Home Study Programs
Log In

The Copay Card Conundrum: Examining the Usage, Regulation, and Management of Direct-to-Consumer Funding Programs

Contact Hours: 1.25. Drug manufacturer copay cards and coupons have been facing increasing criticism and scrutiny by legislators at the federal and state level, as well as by health plan payers, pharmacy benefit managers (PBMs) and employer groups.
Copay Cards
Home Study Programs
Log In

Specialty Pharmaceuticals in Development

Contact Hours 1.25. Over the last several years, approvals of specialty pharmaceuticals have far outpaced those of traditional drugs. It is anticipated that this trend will continue.
Specialty Pharmacy
Home Study Programs
Log In

The Current State of Value-Based Contracting

Contact Hours 1.25. Value-based contracting (VBC) has shown significant promise as an emerging model that rewards value rather than volume in health care.
Value-Based Contracting
Home Study Programs
Log In

Brand and Generic Drugs in Development

Contact Hours: 1.25. This session focuses on new and emerging brand-name drugs, as well as upcoming generic drug approvals.
Brand and Generic Drugs